Adaptive Biotechnologies (ADPT) Q2 FY26 earnings call

Adaptive Biotechnologies delivered an exceptional quarter, marked by robust performance in its MRD business, driven by strong clinical testing volumes and pharma sequencing. The company is actively pursuing the separation of its Immune Medicine business to unlock its full potential, while simultaneously strengthening its financial position. Management remains confident in the long-term trajectory of the MRD business and its ability to generate profitable growth.